urothelial cancer

BMS chases Merck/Seagen with first-line bladder cancer filing
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
Flag link:
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Flag link:
ASCO-GU – Bicycle tries to put distance between itself and Seagen
ASCO-GU – Bicycle tries to put distance between itself and Seagen
EP Vantage
ASCO-GU
Bicycle Therapeutics
Seagen
Padcev
urothelial cancer
BT8009
Flag link:
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Flag link:
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
Flag link:
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Marketwatch
AACR
Bicycle Therapeutics
clinical trials
urothelial cancer
BT8009
Flag link:
The markets refuse to forgive Infinity
The markets refuse to forgive Infinity
EP Vantage
Infinity Pharmaceuticals
eganelisib
urothelial cancer
Flag link:
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
Endpoints
ASCO 2021
Astellas
Seagen
Padcev
FDA
urothelial cancer
Flag link:
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Pharmaceutical Business Review
Seagen
Astellas
clinical trials
EV-201
urothelial cancer
Flag link:
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Flag link:
Esmo 2020 – some backing for Beigene’s unusual combo approach
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
ESMO
BeiGene
urothelial cancer
Flag link:
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Flag link:
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
Xconomy
Urogen
urothelial cancer
FDA
Jelmyto
Flag link:
Seattle Genetics Issue Update on Padcev Label Expansion Study
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Flag link:
Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Here's Why Seattle Genetics Climbed 17.6% in September
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Flag link:
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Flag link:
Seattle Genetics drug could provide new option for bladder cancer patients
Seattle Genetics drug could provide new option for bladder cancer patients
Biopharma Dive
Seattle Genetics
ASCO 2019
enfortumab vedotin
urothelial cancer
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
CP WIre
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:

Pages